Comparing the current results to its competitors, Inari Medical Inc reported Revenue increase in the 3 quarter 2024 by 21.17 % year on year. The sales growth was above Inari Medical Inc 's competitors' average revenue growth of 3.93 %, achieved in the same quarter.
Inari Medical Inc 's Comment on Competition and Industry Peers
The company operates in the medical device industry, focusing on venous thromboembolism (VTE) solutions and emerging therapy clot removal devices. It competes with manufacturers of thrombolytic drugs such as Roche, as well as medical device companies producing thrombectomy devices and systems, including water jets, ultrasonic acoustic field generators, aspirators, and catheters. Key competitors include divisions of Penumbra, Boston Scientific, Abbott, Medtronic, AngioDynamics, Becton Dickinson, and Phillips, along with several smaller firms. The market has seen increased interest in catheter-based solutions for VTE disease, with numerous approved thrombectomy devices available or entering the market, intensifying competition. Currently, no commercially approved devices comparable to the company’s LimFlow system exist. Competitors often have longer operating histories, greater name recognition, and more extensive resources, with some benefiting from established treatment patterns favoring drugs as first-line or concurrent therapies and established relationships with hospitals and physicians. The company’s primary products, the ClotTriever and FlowTriever systems, are designed specifically for the venous system to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) without the use of thrombolytic drugs, aiming to reduce associated costs and complications.
January 17, 2025
In a significant development within the medical sector, Stryker Corporation (NYSE: SYK) has initiated a cash tender offer for all shares of Inari Medical, Inc. (NASDAQ: NARI), valuing each share at $80.00. This announcement, made on January 17, 2025, follows a merger agreement solidified on January 6, underscoring Stryker s strategic intent to expand its operations and product offerings. Facts and Analysis Tender Offer Details: Stryker’s offer to acquire Inari Medical hinges on its ambition to diversify and enhance its portfolio, particularly in minimally invasive technologies, an area where Inari has made significant strides. The acquisition reflects Stryker s ongoing commitment to innovation within the h...
October 15, 2024
In the evolving landscape of thrombosis management, new collaborations and technological advancements are pivotal in enhancing patient outcomes. On October 15, 2024, Inari Medical, Inc. a medical device company committed to transforming the lives of patients with venous and related diseases, announced its partnership with the American Venous Forum (AVF) and the National Blood Clot Alliance (NBCA) to launch the DEFIANCE trial. This announcement coincides with World Thrombosis Day, highlighting an intensified focus on addressing the complexities of deep vein thrombosis (DVT).The DEFIANCE trial is a prospective, multinational, randomized controlled trial designed to investigate the efficacy of Inari s ClotTriev...
Inari Medical Inc, a leading innovator in the field of medical devices, recently announced the enrollment of the first patient in its groundbreaking PEERLESS II Randomized Controlled Trial (RCT). This extensive clinical study aims to revolutionize the treatment guidelines for intermediate-risk Pulmonary Embolism (PE) patients on a global scale. The trial will randomize up to 1,200 patients, making it one of the largest studies of its kind ever conducted. Pulmonary Embolism is a potentially life-threatening condition characterized by the occurrence of blood clots in the lungs. Traditionally, patients with intermediate-risk PE have been treated with anticoagulant therapy alone, which may not alwa...
Livanova Plc is a global medical technology company that focuses on developing and delivering innovative solutions for patients with cardiovascular diseases and neuropsychiatric disorders. Through their diverse portfolio, they offer products and therapies that encompass surgical heart valves, cardiac rhythm management, and neuromodulation. Livanova adopts a patient-centric approach, collaborating with healthcare professionals to improve patient outcomes and enhance quality of life.
Ir med Inc's business model involves providing innovative medical technologies and solutions to the healthcare industry. The company focuses on developing and commercializing advanced medical devices that aim to improve patient outcomes and enhance overall healthcare management.
Icecure Medical Ltd's business model involves the development and commercialization of innovative medical solutions, particularly focused on cryoablation technology.
Integra Lifesciences Holdings Corp's business model revolves around developing, manufacturing, and selling medical devices and instruments to healthcare providers.
Sources:
Inari Medical Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Inari Medical Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
